For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

Tirzepatide (Mounjaro) launched in India in March 2025, promising new hope for diabetes and obesity treatment. An expert ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...

Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...